Celldex Therapeutics, Inc.(CLDX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Celldex Therapeutics, Inc. (CLDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLDX at 8.4/100 on a 32-signal composite quality model, placing it at rank #2,930 of 2,961 stocks — the bottom half of the AI-ranked universe. CLDX scores in the top quartile across institutional flow (95.3). Areas of concern include free cash flow (0.3) and profitability (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Celldex Therapeutics, Inc. reports quarterly revenue of $22.0K, net income of $-73.5M, free cash flow of $-60.6M. Top institutional holders of CLDX by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, BlackRock, Kynam Capital Management, based on the most recent SEC filings. CLDX trades on the Nasdaq exchange and files with the SEC under CIK 744218. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Celldex Therapeutics, Inc. directly from SEC EDGAR.